Goldman Sachs’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Goldman Sachs’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.15M	Buy	1,351,899 +781,475	+137%	+$2.4M	﹤0.01%	3891
2025 Q4	$2.03M	Sell	570,424 -111,219	-16%	-$412K	﹤0.01%	4574
2025 Q3	$2.38M	Buy	681,643 +527,011	+341%	+$1.81M	﹤0.01%	4331
2025 Q2	$317K	Buy	154,632 +39,492	+34%	+$98.7K	﹤0.01%	5411
2025 Q1	$131K	Buy	+115,140	New	+$89.1K	﹤0.01%	5732
2022 Q2	–	Sell	-10,033	Closed	-$72K	–	6721
2022 Q1	$72K	Sell	10,033 -106,065	-91%	-$716K	﹤0.01%	6193
2021 Q4	$1.13M	Buy	116,098 +99,326	+592%	+$883K	﹤0.01%	4737
2021 Q3	$167K	Hold	16,772	–	–	﹤0.01%	5782
2021 Q2	$167K	Buy	+16,772	New	+$169K	﹤0.01%	5806
2021 Q1	–	Sell	-75,000	Closed	-$810K	–	6354
2020 Q4	$810K	Buy	+75,000	New	+$772K	﹤0.01%	4330

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's STLN Position: Q1 2026 in Review

Goldman Sachs increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 137% in Q1 2026, buying an estimated $2.4M and bringing the position to 1,351,899 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3891.

Goldman Sachs first reported a position in STLN in Q4 2020 and has held it in 10 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Goldman Sachs held 1,351,899 shares of Starling Oncology Institute, Inc. Common Stock worth $4.15M as of Q1 2026.
Goldman Sachs bought 781,475 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $2.4M.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3891 holding.
Goldman Sachs first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and has held it in 10 quarters since.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.